Uta Griesenbach

Cell and Gene Therapy Catapult — United Kingdom

Medicine · Health Sciences

40h-index5.2kcitations244works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cystic Fibrosis Research Advances(86), Virus-based gene therapy research(78), Neonatal Respiratory Health Research(67), Viral gastroenteritis research and epidemiology(39), Respiratory viral infections research(38)

Publications244 total

F/HN-pseudotyped lentiviral vector efficiently transduces non-human primate airways with no evidence of relevant toxicity
Molecular Therapy Advances·2025Open Access
Potential gene therapies for cystic fibrosis: a plain language summary for non-specialists and the lay community
Future Rare Diseases·2025
Intranasal delivery of mRNA expressing newly identified Acinetobacter baumannii antigens protects against bacterial lung disease
npj Vaccines·2025· 4 citedOpen Access
Increased NFAT and NFκB signalling contribute to the hyperinflammatory phenotype in response to Aspergillus fumigatus in a mouse model of cystic fibrosis
PLoS Pathogens·2025· 4 citedOpen Access
Increased NFAT and NFκB signalling contribute to the hyperinflammatory phenotype in response to <i>Aspergillus fumigatus</i> in cystic fibrosis
2024Open Access
Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial
American Journal of Respiratory and Critical Care Medicine·2024· 25 citedOpen Access
Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy
European Respiratory Journal·2024· 2 citedOpen Access
P045 Lenticlair™ 1: A phase 1/2 trial evaluating the safety, tolerability and efficacy of an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF ineligible for CFTR modulators
Journal of Cystic Fibrosis·2024
P046 Lenticlair™-ON: An extension trial examining long-term safety and efficacy outcomes associated with an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with cystic fibrosis
Journal of Cystic Fibrosis·2024
WS10.01 Administration of lentiviral vector doses achieving high transduction efficiency is well tolerated in mice
Journal of Cystic Fibrosis·2024
The British Society for Gene and Cell Therapy at 20 (2003–2023)
Human Gene Therapy·2023
Exploring current shortfalls and potential improvements for non-viral gene delivery in cystic fibrosis
Cell and Gene Therapy Insights·2023
WS17.06 F/HN pseudotyped lentiviral vector-mediated transduction of non-human primates
Journal of Cystic Fibrosis·2023· 1 citedOpen Access
Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis
Journal of Cystic Fibrosis·2023· 22 citedOpen Access
Progress in Respiratory Gene Therapy
Human Gene Therapy·2022· 24 citedOpen Access
Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression
Molecular Therapy — Methods & Clinical Development·2022· 1 citedOpen Access
597: Protocol development for mouse toxicology studies using lentiviral gene therapy
Journal of Cystic Fibrosis·2021Open Access
605: Development of molecular assays to determine gene transfer efficiency in an upcoming first-in-man CF lentivirus trial
Journal of Cystic Fibrosis·2021Open Access
528: Computational tools for quantification of gene transfer efficiency in lung tissue
Journal of Cystic Fibrosis·2021Open Access
The British Society for Gene and Cell Therapy
Human Gene Therapy·2021
page 1 of 13Next →

Frequent Co-authors

Eric W.F.W. Alton(45), Stephen C. Hyde(16), Jane C. Davies(15), Deborah R. Gill(15), David J. Porteous(12), J. Alastair Innes(10), D M Geddes(9), Tracy Higgins(8), Stefano Ferrari(8), Alan Boyd(8), Mario Chan(7), Seng H. Cheng(7), Duncan M. Geddes(7), Gerry McLachlan(7), Ian A. Pringle(7), Mamoru Hasegawa(7), Stephanie Jones(6), Peter K. Jeffery(6), Makoto Inoue(6), A. Christopher Boyd(5)